Boehringer Ingelheim Canada Ltd
Registration:
32
of
34
(2023-08-15
to
2024-01-01)
Details Regarding the Identified Subject Matter
|
Specific Topics of Lobbying Communications
|
Intended Outcomes
|
Associated Subject Matters
|
Discuss healthcare improvement partnerships
|
Development of any legislative proposal by the government of British Columbia, a Provincial entity or a member of the Legislative Assembly
|
Indigenous Relations and Reconciliation
|
Facilitate the development of framework to enable public-private-partnerships to support health system efficiency and patient outcomes. An example is our partnership with the Canadian Foundation for Healthcare Improvement (CFHI).
|
Development of any legislative proposal by the government of British Columbia, a Provincial entity or a member of the Legislative Assembly
|
Economic Development and Trade, Health
|
Providing education regarding healthcare innovation, pharmaceutical investment, health policy and patient-centered initiatives in BC
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Science and Technology
|
To actively promote the contributions and positive impact of pharmaceutical innovation and the innovative pharmaceutical industry in British Columbia and to increase awareness of the value of innovative therapies on the healthcare system. Ensure any changes to pharmaceutical legislation support appropriate government reimbursement of innovative pharmaceuticals. Work with the Ministry of Health regarding public reimbursement of our innovative pharmaceutical products
|
Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation
|
Health
|